US Pharma MarketingThe post ASCO26: AstraZeneca’s light chain amyloidosis shows subgroup benefit after Phase III trial appeared first on Clinical Trials Arena.
ASCO26: AstraZeneca’s light chain amyloidosis shows subgroup benefit after Phase III trial
The data on the kappa AL amyloidosis group treated with anselamimab was presented by AstraZeneca at ASCO 2026. The data on the kappa AL amyloidosis group treated with anselamimab was presented by AstraZeneca at ASCO 2026. The data on the full population was published in July 2025. Credit: Andrea Aimar / Shutterstock.com AstraZeneca’s investigational anti-fibril therapy, anselamimab, did not meet its primary endpoint in a Phase III trial in the overall light chain amyloidosis population, but showed benefit in kappa patients. In the global CARES programme, which enrolled patients with Mayo stages IIIa (NCT04512235) and Mayo stages IIIb (NCT04504825), the…
The data on the kappa AL amyloidosis group treated with anselamimab was presented by AstraZeneca at ASCO 2026.
Source: Clinical Trials Arena